华熙生物发布2025年度业绩快报 结构调整深化，盈利能力持续提升

Core Viewpoint - Huaxi Biological Technology Co., Ltd. reported a significant transformation in its operational strategy, shifting from scale expansion to quality improvement, resulting in enhanced profitability despite a decline in revenue [1][4]. Financial Performance - In 2025, the company achieved total operating revenue of 4.217 billion yuan, a year-on-year decrease of 21.49% [1]. - The net profit attributable to shareholders was 291 million yuan, reflecting a year-on-year increase of 67.03% [1]. - The net profit after deducting non-recurring gains and losses reached 188 million yuan, up 75.28% year-on-year [1]. - The weighted average return on net assets was 4.17%, an increase of 1.62 percentage points compared to the previous year [1]. Business Strategy - The decline in revenue was primarily due to systematic structural optimization in skin science and nutrition science innovation businesses, focusing on core brands and key categories [2]. - The company reduced investment in less efficient brands and projects, concentrating resources on areas with technological foundations and product accumulation [2]. - Management expenses decreased by over 10% year-on-year, contributing to profit growth through effective cost control [2]. - Sales expenses dropped by over 30% year-on-year, further enhancing profitability amid revenue pressure [2]. Research and Innovation - The company is advancing research in glycoscience and cell biology, focusing on extracellular matrix regulation mechanisms for aging intervention and tissue regeneration [3]. - It is enhancing the industrialization capability of bioactive substances and regenerative materials through a synthetic biology research and development system [3]. - Digitalization and AI technologies are being applied in production, supply chain management, and internal operations to improve overall operational efficiency [3]. Future Outlook - The 2025 performance reflects the results of organizational optimization, business focus, technological innovation, and digital empowerment [4]. - The company aims to continue building core capabilities around synthetic biology technology and industrialization to enhance operational quality and sustainable development [4].